The paradoxical association between tension-reduction alcohol outcome expectancies and tension following alcohol consumption.

Background: Behavioral models suggest that strong tension-reduction alcohol-outcome expectancies (TREs) among drinkers should be associated with greater tension reduction after drinking. Yet, the few studies investigating this have found either no relationship or the opposite relationship.Objectives: We sought to explore this relationship by building upon the limitations of past studies and employing a placebo-controlled, within-subject experimental design.Methods: Sixty social drinkers (26 M, 34 F) visited the lab on two occasions spaced one week apart. Each participant was randomly assigned to receive alcoholic drinks targeting a BAC of 0.05% on one testing day and placebo drinks on the other, with the order counter-balanced. On both testing days, participants completed measures of state anxiety and fear both before drinking and following a drinking/absorption period. While completing the self-report measures, participants were anticipating an impending, mildly stressful heartbeat perception task.Results: Multilevel modeling revealed that the more strongly individuals believed that alcohol reduces tension, the less the pharmacologic properties of alcohol did so (p = .02 for the state anxiety outcome measure; p = .001 for the fear outcome measure). This was the case even with anxiety sensitivity - a known predictor of stress-response dampening - controlled for.Conclusions: These results provide further evidence for the paradoxical association of TREs and the dampening of anxiety. Additionally, the findings are consistent with the basis of expectancy challenges that aim to reframe inaccurate TREs among drinkers.

Sensitivity and bias in the discrimination of two-dimensional and three-dimensional motion direction.

Sensory systems are faced with an essentially infinite number of possible environmental events but have limited processing resources. Posed with this challenge, it makes sense to allocate these resources to prioritize the discrimination of events with the most behavioral relevance. Here, we asked if such relevance is reflected in the processing and perception of motion. We compared human performance on a rapid motion direction discrimination task, including monocular and binocular viewing. In particular, we determined sensitivity and bias for a binocular motion-in-depth (three-dimensional; 3D) stimulus and for its constituent monocular (two-dimensional; 2D) signals over a broad range of speeds. Consistent with prior work, we found that binocular 3D sensitivity was lower than monocular sensitivity for all speeds. Although overall sensitivity was worse for 3D discrimination, we found that the transformation from 2D to 3D motion processing also incorporated a pattern of potentially advantageous biases. One such bias is reflected by a criterion shift that occurs at the level of 3D motion processing and results in an increased hit rate for motion toward the head. We also observed an increase in sensitivity for 3D motion trajectories presented on crossed rather than uncrossed disparity pedestals, privileging motion trajectories closer to the observer. We used these measurements to determine the range of real-world trajectories for which rapid 3D motion discrimination is most useful. These results suggest that the neural mechanisms that underlie motion perception privilege behaviorally relevant motion and provide insights into the nature of human motion sensitivity in the real world.

Association of Missense Mutation in FOLH1 With Decreased NAAG Levels and Impaired Working Memory Circuitry and Cognition.

OBJECTIVE: Altering the metabotropic glutamate receptor 3 (mGluR3) by pharmacology or genetics is associated with differences in learning and memory in animals and humans. GRM3 (the gene coding for mGluR3) is also genome-wide associated with risk for schizophrenia. The neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) is the selective endogenous agonist of mGluR3, and increasing NAAG may improve cognition. Glutamate carboxypeptidase II (GCPII), coded by the gene folate hydrolase 1 (FOLH1), regulates the amount of NAAG in the synapse. The goal of this study was to determine the relationship between FOLH1, NAAG levels, measures of human cognition, and neural activity associated with cognition. METHODS: The effects of genetic variation in FOLH1 on mRNA expression in human brain and NAAG levels using 7-T magnetic resonance spectroscopy (MRS) were measured. NAAG levels and FOLH1 genetic variation were correlated with measures of cognition in subjects with psychosis and unaffected subjects. Additionally, FOLH1 genetic variation was correlated with neural activity during working memory, as measured by functional MRI (fMRI). RESULTS: A missense mutation in FOLH1 (rs202676 G allele) was associated with increased FOLH1 mRNA in the dorsolateral prefrontal cortex of brains from unaffected subjects and schizophrenia patients. This FOLH1 variant was associated with decreased NAAG levels in unaffected subjects and patients with psychosis. NAAG levels were positively correlated with visual memory performance. Carriers of the FOLH1 variant associated with lower NAAG levels had lower IQ scores. Carriers of this FOLH1 variant had less efficient cortical activity during working memory. CONCLUSIONS: These data show that higher NAAG levels are associated with better cognition, suggesting that increasing NAAG levels through FOLH1/GCPII inhibition may improve cognition. Additionally, NAAG levels measured by MRS and cortical efficiency during working memory measured by fMRI have the potential to be neuroimaging biomarkers for future clinical trials.

Nimodipine improves cortical efficiency during working memory in healthy subjects.

The L-type calcium channel gene, CACNA1C, is a validated risk gene for schizophrenia and the target of calcium channel blockers. Carriers of the risk-associated genotype (rs1006737 A allele) have increased frontal cortical activity during working memory and higher CACNA1C mRNA expression in the prefrontal cortex. The aim of this study was to determine how the brain-penetrant calcium channel blocker, nimodipine, changes brain activity during working memory and other cognitive and emotional processes. We conducted a double-blind randomized cross-over pharmacoMRI study of a single 60 mg dose of oral nimodipine solution and matching placebo in healthy men, prospectively genotyped for rs1006737. With performance unchanged, nimodipine significantly decreased frontal cortical activity by 39.1% and parietal cortical activity by 42.8% during the N-back task (2-back > 0-back contrast; PFWE < 0.05; n = 28). Higher peripheral nimodipine concentrations were correlated with a greater decrease in activation in the frontal cortex. Carriers of the risk-associated allele, A (n = 14), had a greater decrease in frontal cortical activation during working memory compared to non-risk allele carriers. No differences in brain activation were found between nimodipine and placebo for other tasks. Future studies should be conducted to test if the decreased cortical brain activity after nimodipine is associated with improved working memory performance in patients with schizophrenia, particularly those who carry the risk-associated genotype. Furthermore, changes in cortical activity during working memory may be a useful biomarker in future trials of L-type calcium channel blockers.